Bereich
Brustzentrum St.Gallen
BZ · Dept. IV
Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial
Gerber B, Untch M, Kast K, Jackisch C, Thomalla J, Seither F, Blohmer J, Rhiem K, Fasching P, Nekljudova V, Loibl S, Hahn M, Klare P, Ataseven B, Schneeweiss A, Möbus V, Golatta M, Tesch H, Krug D, Hanusch C, Denkert C, Lübbe K, Heil J, Huober J, Kühn T. Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. Cancers (Basel) 2022; 14
20.01.2022Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial
20.01.2022Cancers (Basel) 2022; 14
Gerber Bernd, Untch Michael, Kast Karin, Jackisch Christian, Thomalla Jörg, Seither Fenja, Blohmer Jens-Uwe, Rhiem Kerstin, Fasching Peter A, Nekljudova Valentina, Loibl Sibylle, Hahn Markus, Klare Peter, Ataseven Beyhan, Schneeweiss Andreas, Möbus Volker, Golatta Michael, Tesch Hans, Krug David, Hanusch Claus, Denkert Carsten, Lübbe Kristina, Heil Jörg, Huober Jens, Kühn Thorsten
Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex
van Rees D, Saura C, Di Cosimo S, Huober J, Roylance R, Kim S, Kuijpers T, van Bruggen R, K van den Berg T, Guillaume S, Izquierdo M, El-Abed S, Bouti P, Klein B, Verkuijlen P, van Houdt M, Schornagel K, Tool A, Venet D, Sotiriou C, Matlung H. Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex. J Immunother Cancer 2022; 10
01.01.2022Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex
01.01.2022J Immunother Cancer 2022; 10
van Rees Dieke J, Saura Cristina, Di Cosimo Serena, Huober Jens, Roylance Rebecca, Kim Sung-Bae, Kuijpers Taco W, van Bruggen Robin, K van den Berg Timo, Guillaume Sébastien, Izquierdo Miguel, El-Abed Sarra, Bouti Panagiota, Klein Bart, Verkuijlen Paul J H, van Houdt Michel, Schornagel Karin, Tool Anton T J, Venet David, Sotiriou Christos, Matlung Hanke L
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial
Blohmer J, Jackisch C, Rhiem K, Solbach C, Hanusch C, Seither F, Denkert C, Engels K, Nekljudova V, Loibl S, Thill M, Huober J, Link T, Reinisch M, Just M, Untch M, Stötzer O, Fasching P, Schneeweiss A, Wimberger P, Seiler S, GBG and AGO-B. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial. JAMA Oncol 2022; 8:1010-1018.
01.01.2022Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial
01.01.2022JAMA Oncol 2022; 8:1010-1018
Blohmer Jens-Uwe, Jackisch Christian, Rhiem Kerstin, Solbach Christine, Hanusch Claus, Seither Fenja, Denkert Carsten, Engels Knut, Nekljudova Valentina, Loibl Sibylle, Thill Marc, Huober Jens, Link Theresa, Reinisch Mattea, Just Marianne, Untch Michael, Stötzer Oliver, Fasching Peter A, Schneeweiss Andreas, Wimberger Pauline, Seiler Sabine, GBG and AGO-B
What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
Pizzamiglio S, Huober J, Ellard S, Rimm D, Gombos A, Daidone M, Verderio P, Tagliabue E, Di Cosimo S, Nuciforo P, Bajji M, Cosentino G, Ciniselli C, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El-Abed S, Wang Y, Iorio M. What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. Cancer Med 2021; 11:332-339.
17.12.2021What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
17.12.2021Cancer Med 2021; 11:332-339
Pizzamiglio Sara, Huober Jens, Ellard Susan L, Rimm David L, Gombos Andrea, Daidone Maria Grazia, Verderio Paolo, Tagliabue Elda, Di Cosimo Serena, Nuciforo Paolo, Bajji Mohammed, Cosentino Giulia, Ciniselli Chiara M, De Cecco Loris, Cataldo Alessandra, Plantamura Ilaria, Triulzi Tiziana, El-Abed Sarra, Wang Yingbo, Iorio Marilena V
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
Müller V, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T, Hoffmann O, Rübner M, Huober J, Banys-Paluchowski M, Friedl T, Fasching P, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, DETECT study group. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open 2021; 6:100299.
25.11.2021Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
25.11.2021ESMO Open 2021; 6:100299
Müller V, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T, Hoffmann O, Rübner M, Huober Jens, Banys-Paluchowski M, Friedl T W P, Fasching P A, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, DETECT study group
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
Schneeweiss A, Blohmer J, Fasching P, Solbach C, Schmutzler R, Huober J, Rhiem K, Nekljudova V, Lübbe K, Loibl S, Jackisch C, Untch M, Link T, Michel L, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, Kast K, Pohl-Rescigno E, Hanusch C, GBG and AGO-B. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. Eur J Cancer 2021
17.11.2021Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
17.11.2021Eur J Cancer 2021
Schneeweiss Andreas, Blohmer Jens-Uwe, Fasching Peter A, Solbach Christine, Schmutzler Rita K, Huober Jens, Rhiem Kerstin, Nekljudova Valentina, Lübbe Kristina, Loibl Sibylle, Jackisch Christian, Untch Michael, Link Theresa, Michel Laura L, Möbus Volker, Tesch Hans, Klare Peter, Hahnen Eric, Denkert Carsten, Kast Karin, Pohl-Rescigno Esther, Hanusch Claus, GBG and AGO-B
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
Metzger-Filho O, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans W, Geyer C, Loibl S, Sikov W, Golshan M, Collier K, Asad S, Ansell P, Watson M, Bae J, Cherian M, O'Shaughnessy J, Untch M, Rugo H, Huober J, Stover D. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. NPJ Breast Cancer 2021; 7:142.
11.11.2021Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
11.11.2021NPJ Breast Cancer 2021; 7:142
Metzger-Filho Otto, von Minckwitz Gunter, Rastogi Priya, Li Lang, Cheng Lijun, Maag David, Wolmark Norman, Denkert Carsten, Symmans W Fraser, Geyer Charles E, Loibl Sibylle, Sikov William M, Golshan Mehra, Collier Katharine, Asad Sarah, Ansell Peter J, Watson Mark, Bae Junu, Cherian Mathew, O'Shaughnessy Joyce, Untch Michael, Rugo Hope S, Huober Jens, Stover Daniel G
Correction: AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update
Ditsch N, Rody A, Rhiem K, Reimer T, Park-Simon T, Nitz U, Mundhenke C, Möbus V, Maass N, Lux M, Luftner D, Schmidt M, Schneeweiss A, Thill M, Wöckel A, Witzel I, Untch M, Thomssen C, Stickeler E, Solomayer E, Solbach C, Sinn H, Schütz F, Loibl S, Kümmel S, Blohmer J, Bauerfeind I, Albert U, Krug D, Jackisch C, Kolberg-Liedtke C, Banys-Paluchowski M, Müller V, Janni W, Kühn T, Budach W, Dall P, Kreipe H, Huober J, Heil J, Harbeck N, Hanf V, Gluz O, Gerber B, Fehm T, Fasching P, Fallenberg E, Friedrich M. Correction: AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. Geburtshilfe Frauenheilkd 2021; 81:e31.
22.10.2021Correction: AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update
22.10.2021Geburtshilfe Frauenheilkd 2021; 81:e31
Ditsch Nina, Rody Achim, Rhiem Kerstin, Reimer Toralf, Park-Simon Tjoung-Won, Nitz Ulrike, Mundhenke Christoph, Möbus Volker, Maass Nicolai, Lux Michael Patrick, Luftner Diana, Schmidt Marcus, Schneeweiss Andreas, Thill Marc, Wöckel Achim, Witzel Isabell, Untch Michael, Thomssen Christoph, Stickeler Elmar, Solomayer Erich-Franz, Solbach Christine, Sinn Hans-Peter, Schütz Florian, Loibl Sibylle, Kümmel Sherko, Blohmer Jens, Bauerfeind Ingo, Albert Ute-Susann, Krug David, Jackisch Christian, Kolberg-Liedtke Cornelia, Banys-Paluchowski Maggie, Müller Volkmar, Janni Wolfgang, Kühn Thorsten, Budach Wilfried, Dall Peter, Kreipe Hans-Heinrich, Huober Jens, Heil Jörg, Harbeck Nadia, Hanf Volker, Gluz Oleg, Gerber Bernd, Fehm Tanja, Fasching Peter A, Fallenberg Eva M, Friedrich Michael
Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa)
Merzenich H, Wollschläger D, Blettner M, Wiegel T, Bartkowiak D, Woeckel A, Janni W, Schwentner L, Bekes I, Schmidt M, Baaken D, Schmidberger H. Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa). Breast Cancer Res Treat 2021
09.10.2021Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa)
09.10.2021Breast Cancer Res Treat 2021
Merzenich Hiltrud, Wollschläger Daniel, Blettner Maria, Wiegel Thomas, Bartkowiak Detlef, Woeckel Achim, Janni Wolfgang, Schwentner Lukas, Bekes Inga, Schmidt Marcus, Baaken Dan, Schmidberger Heinz
AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update
Ditsch N, Rody A, Rhiem K, Reimer T, Park-Simon T, Nitz U, Mundhenke C, Möbus V, Maass N, Lux M, Luftner D, Schmidt M, Schneeweiss A, Thill M, Wöckel A, Witzel I, Untch M, Thomssen C, Stickeler E, Solomayer E, Solbach C, Sinn H, Schütz F, Loibl S, Kümmel S, Blohmer J, Bauerfeind I, Albert U, Krug D, Jackisch C, Kolberg-Liedtke C, Banys-Pachulowski M, Müller V, Janni W, Kühn T, Budach W, Dall P, Kreipe H, Huober J, Heil J, Harbeck N, Hanf V, Gluz O, Gerber B, Fehm T, Fasching P, Fallenberg E, Friedrich M. AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. Geburtshilfe Frauenheilkd 2021; 81:1112-1120.
06.10.2021AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update
06.10.2021Geburtshilfe Frauenheilkd 2021; 81:1112-1120
Ditsch Nina, Rody Achim, Rhiem Kerstin, Reimer Toralf, Park-Simon Tjoung-Won, Nitz Ulrike, Mundhenke Christoph, Möbus Volker, Maass Nicolai, Lux Michael Patrick, Luftner Diana, Schmidt Marcus, Schneeweiss Andreas, Thill Marc, Wöckel Achim, Witzel Isabell, Untch Michael, Thomssen Christoph, Stickeler Elmar, Solomayer Erich-Franz, Solbach Christine, Sinn Hans-Peter, Schütz Florian, Loibl Sibylle, Kümmel Sherko, Blohmer Jens, Bauerfeind Ingo, Albert Ute-Susann, Krug David, Jackisch Christian, Kolberg-Liedtke Cornelia, Banys-Pachulowski Maggie, Müller Volkmar, Janni Wolfgang, Kühn Thorsten, Budach Wilfried, Dall Peter, Kreipe Hans-Heinrich, Huober Jens, Heil Jörg, Harbeck Nadia, Hanf Volker, Gluz Oleg, Gerber Bernd, Fehm Tanja, Fasching Peter A, Fallenberg Eva M, Friedrich Michael
Team functioning across different tumour types: Insights from a Swiss cancer center using qualitative and quantitative methods.
Hitz F, Ribi K, Grote G, Kolbe M, Schmitz C, Lamb B, Ruhstaller T, Berchtold P, Sevdalis N. Team functioning across different tumour types: Insights from a Swiss cancer center using qualitative and quantitative methods. Cancer Rep (Hoboken) 2021; 5:e1541.
28.09.2021Team functioning across different tumour types: Insights from a Swiss cancer center using qualitative and quantitative methods.
28.09.2021Cancer Rep (Hoboken) 2021; 5:e1541
Hitz Felicitas, Ribi Karin, Grote Gudela, Kolbe Michaela, Schmitz Christof, Lamb Benjamin W, Ruhstaller Thomas, Berchtold Peter, Sevdalis Nick
Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
Pizzamiglio S, Cappelletti V, Cinieri S, Piccart M, Daidone M, Pruneri G, Colombo M, Tagliabue E, Verderio P, Huober J, Nuciforo P, Izquierdo M, Ciniselli C, Triulzi T, Gargiuli C, De Cecco L, de Azambuja E, Fumagalli D, Sotiriou C, Harbeck N, Di Cosimo S. Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. Clin Cancer Res 2021; 27:6307-6313.
21.09.2021Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
21.09.2021Clin Cancer Res 2021; 27:6307-6313
Pizzamiglio Sara, Cappelletti Vera, Cinieri Saverio, Piccart Martine, Daidone Maria Grazia, Pruneri Giancarlo, Colombo Mario Paolo, Tagliabue Elda, Verderio Paolo, Huober Jens, Nuciforo Paolo, Izquierdo Miguel, Ciniselli Chiara Maura, Triulzi Tiziana, Gargiuli Chiara, De Cecco Loris, de Azambuja Evandro, Fumagalli Debora, Sotiriou Christos, Harbeck Nadia, Di Cosimo Serena
Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors
De Gregorio A, Friedl T, Hering E, Widschwendter P, De Gregorio N, Bekes I, Janni W, Davut D, Huober J. Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors. Oncology 2021; 99:780-789.
14.09.2021Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors
14.09.2021Oncology 2021; 99:780-789
De Gregorio Amelie, Friedl Thomas Wolfram Paul, Hering Eva, Widschwendter Peter, De Gregorio Nikolaus, Bekes Inga, Janni Wolfgang, Davut Dayan, Huober Jens
Update Swiss guideline for counselling and testing for predisposition to breast, ovarian, pancreatic and prostate cancer
Stoll S, Unger S, Azzarello-Burri S, Chappuis P, Graffeo R, Pichert G, Röthlisberger B, Taban F, Riniker S. Update Swiss guideline for counselling and testing for predisposition to breast, ovarian, pancreatic and prostate cancer. Swiss Med Wkly 2021; 151:w30038.
13.09.2021Update Swiss guideline for counselling and testing for predisposition to breast, ovarian, pancreatic and prostate cancer
13.09.2021Swiss Med Wkly 2021; 151:w30038
Stoll Susanna, Unger Sheila, Azzarello-Burri Silvia, Chappuis Pierre, Graffeo Rossella, Pichert Gabriella, Röthlisberger Benno, Taban Francois, Riniker Salome
Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
Knauer M, Winkler J, Reinisch M, Reitsamer R, Singer C, Reisenberger K, Hager C, Fansa H, Exner R, Dubsky P, Berclaz G, Leo C, Lam G, Fehr M, Naydina T, Heil J, Egle D, Lelièvre L, Markellou P, Schulz A, Maggi N, Nussbaumer R, Fitzal F, Ostapenko V, Clerc K, Kohlik M, Dedes K, Sarlos D, Muenst S, Ruhstaller T, Maddox C, Seiler S, Zimmermann F, Gruber G, Zwahlen D, Henke G, Tausch C, Hayoz S, Matrai Z, Ackerknecht M, Kuemmel S, Bjelic-Radisic V, Maráz R, Gabriel N, Fehr P, Simonson C, Bucher S, Becciolini C, Meyer I, Satler R, Vrieling C, Újhelyi M, Kurzeder C, Weber W. Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). Breast 2021; 60:98-110.
08.09.2021Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
08.09.2021Breast 2021; 60:98-110
Knauer Michael, Winkler Jelena, Reinisch Mattea, Reitsamer Roland, Singer Christian F, Reisenberger Klaus, Hager Christopher, Fansa Hisham, Exner Ruth, Dubsky Peter, Berclaz Gilles, Leo Cornelia, Lam Giang Thanh, Fehr Mathias K, Naydina Tatiana, Heil Jörg, Egle Daniel, Lelièvre Loic, Markellou Pagona, Schulz Alexandra, Maggi Nadia, Nussbaumer Rahel, Fitzal Florian, Ostapenko Valerijus, Clerc Karine, Kohlik Magdalena, Dedes Konstantin J, Sarlos Dimitri, Muenst Simone, Ruhstaller Thomas, Maddox Charlotte, Seiler Stefanie, Zimmermann Frank, Gruber Günther, Zwahlen Daniel R, Henke Guido, Tausch Christoph, Hayoz Stefanie, Matrai Zoltan, Ackerknecht Markus, Kuemmel Sherko, Bjelic-Radisic Vesna, Maráz Robert, Gabriel Natalie, Fehr Peter M, Simonson Colin, Bucher Susanne, Becciolini Charles, Meyer Inna, Satler Rok, Vrieling Conny, Újhelyi Mihály, Kurzeder Christian, Weber Walter P
Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer
Vathiotis I, Kim S, Harbeck N, Gomez H, Shafi S, Syrigos K, Fountzilas G, Sotiriou C, Pusztai L, Warren S, Di Cosimo S, Huober J, Nuciforo P, Moutafi M, Divakar P, Aung T, Qing T, Fernandez A, Yaghoobi V, El-Abed S, Wang Y, Guillaume S, Rimm D. Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer. Clin Cancer Res 2021
31.08.2021Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer
31.08.2021Clin Cancer Res 2021
Vathiotis Ioannis A, Kim Sung-Bae, Harbeck Nadia, Gomez Henry, Shafi Saba, Syrigos Konstantinos N, Fountzilas George, Sotiriou Christos, Pusztai Lajos, Warren Sarah, Di Cosimo Serena, Huober Jens, Nuciforo Paolo, Moutafi Myrto K, Divakar Prajan, Aung Thazin Nwe, Qing Tao, Fernandez Aileen, Yaghoobi Vesal, El-Abed Sarra, Wang Yingbo, Guillaume Sébastien, Rimm David L
Fertility and breast cancer: A literature review of counseling, preservation options and outcomes.
Moragón S, Di Liello R, Bermejo B, Hernando C, Olcina Aguado E, Chirivella I, Lluch A, Cejalvo J, Martínez M. Fertility and breast cancer: A literature review of counseling, preservation options and outcomes. Crit Rev Oncol Hematol 2021; 166:103461.
27.08.2021Fertility and breast cancer: A literature review of counseling, preservation options and outcomes.
27.08.2021Crit Rev Oncol Hematol 2021; 166:103461
Moragón Santiago, Di Liello Raimondo, Bermejo Begoña, Hernando Cristina, Olcina Aguado Ernesto Francisco, Chirivella Isabel, Lluch Ana, Cejalvo Juan Miguel, Martínez María Teresa
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer
Jhaveri K, De Vita S, Crystal A, He W, Ji Y, Balbin A, Sheng Q, Kundamal N, Huober J, Takahashi S, Terret C, Duhoux F, Layman R, Cresta S, Yap Y, Juric D, Curigliano G. A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res 2021
25.08.2021A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer
25.08.2021Clin Cancer Res 2021
Jhaveri Komal, De Vita Serena, Crystal Adam, He Wei, Ji Yan, Balbin Alejandro, Sheng Qing, Kundamal Nicole, Huober Jens, Takahashi Shunji, Terret Catherine, Duhoux Francois P, Layman Rachel M, Cresta Sara, Yap Yoon-Sim, Juric Dejan, Curigliano Giuseppe
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)
Möbus V, Reinisch M, Link T, Sinn B, Janni W, Denkert C, Furlanetto J, Engels K, Solbach C, Schmatloch S, Rey J, Burchardi N, Loibl S, Stickeler E, Huober J, Lück H, Ladda E, Klare P, Schmidt M, Schneeweiss A, Grischke E, Wachsmann G, Forstbauer H, Untch M, Marme F, Blohmer J, Jackisch C, GBG and AGO-B. Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). Eur J Cancer 2021; 156:138-148.
24.08.2021Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)
24.08.2021Eur J Cancer 2021; 156:138-148
Möbus Volker, Reinisch Mattea, Link Theresa, Sinn Bruno V, Janni Wolfgang, Denkert Carsten, Furlanetto Jenny, Engels Knut, Solbach Christine, Schmatloch Sabine, Rey Julia, Burchardi Nicole, Loibl Sibylle, Stickeler Elmar, Huober Jens, Lück Hans-Joachim, Ladda Ekkehart, Klare Peter, Schmidt Marcus, Schneeweiss Andreas, Grischke Eva-Maria, Wachsmann Grischa, Forstbauer Helmut, Untch Michael, Marme Frederik, Blohmer Jens-Uwe, Jackisch Christian, GBG and AGO-B
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial
Friedl T, Tesch H, Mahner S, Brucker S, Heinrich G, Häberle L, Fasching P, Beckmann M, Coleman R, Janni W, Schneeweiss A, Jückstock J, Fehm T, Müller V, Lichtenegger W, Blohmer J, Lorenz R, Forstbauer H, Fink V, Bekes I, Huober J, Rack B. Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial. JAMA Oncol 2021; 7:1149-1157.
01.08.2021Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial
01.08.2021JAMA Oncol 2021; 7:1149-1157
Friedl Thomas W P, Tesch Hans, Mahner Sven, Brucker Sara Y, Heinrich Georg, Häberle Lothar, Fasching Peter A, Beckmann Matthias W, Coleman Robert E, Janni Wolfgang, Schneeweiss Andreas, Jückstock Julia, Fehm Tanja, Müller Volkmar, Lichtenegger Werner, Blohmer Jens, Lorenz Ralf, Forstbauer Helmut, Fink Visnja, Bekes Inga, Huober Jens, Rack Brigitte